Inhibition of matrix metalloproteinases prevents cardiac hypertrophy induced by β-adrenergic stimulation in rats

Journal of Cardiovascular Pharmacology

Volumn 42, Issue 2, 2003, Pages 174-181

  Miura, Shoko ^a   Ohno, Isao ^b   Suzuki, Jun ^a   Suzuki, Ko ^c   Okada, Shinji ^b   Okuyama, Akira ^d   Nawata, Jun ^a   Ikeda, Jun ^a   Shirato, Kunio ^a,b  

^a Dept of Cardiovascular Medicine ^*  (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c Miyagi Red Cross Blood Center   (Japan)

^d TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Adrenergic; Enzyme; Growth factors; Hypertrophy; Myocytes

Indexed keywords

GELATINASE A; INTERSTITIAL COLLAGENASE; ISOPRENALINE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; SI 27; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BETA ADRENERGIC STIMULATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; HEART VENTRICLE HYPERTROPHY; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RAT; TISSUE DISTRIBUTION; WESTERN BLOTTING;

ANIMALS; CARDIOMEGALY; CARDIOTONIC AGENTS; INSULIN-LIKE GROWTH FACTOR I; ISOPROTERENOL; MALE; MATRIX METALLOPROTEINASES; RATS; RATS, WISTAR;

EID: 0042303831     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200308000-00004     Document Type: Article

References (34)

1. Decker RS, Cook MG, Behnke-Barcley M, et al. Some growth factors stimulate cultured adult rabbit ventricular myocyte hypertrophy in the absence of mechanical loading. Circ Res. 1995;77:544-555.
2. Suzuki J, Ohno I, Nawata J, et al. Overexpression of insulin-like growth factor-I in hearts of rats with isoproterenol-induced cardiac hypertrophy. J Cardiovasc Pharmacol. 1999;34:635-644.
3. Sun X, Ng Y-C. Effects of norepinephrine on expression of IGF-1/IGF-1R and SERCA2 in rat heart. Cardiovasc Res. 1998;37:202-209.
4. Collett-Solberg PF, Cohen P. The role of the insulin-like growth factor binding proteins and the IGFBP proteases in modulating IGF action. Endocrinol Metab Clin North Am. 1996;25:591-614.
5. Kluge A, Zimmermann R, Weihrauch D, et al. Coordinate expression of the insulin-like growth factor system after microembolisation in porcine heart. Cardiovasc Res. 1997;33:324-331.
6. Han VKM, Matsell DG, Delhanty PJD, et al. IGF-binding protein mRNAs in the human fetus: tissue and cellular distribution of developmental expression. Horm Res. 1996;45:160-166.
7. Fowlkes JL, Thrailkill KM, Serra DM, et al. Matrix metalloproteinases as insulin-like growth factor binding protein-degrading proteinases. Prog Growth Factor Res. 1995;6:255-263.
8. Rajah R, Nachajon RV, Collins MH, et al. Elevated levels of the IGF-binding protein protease MMP-1 in asthmatic airway smooth muscle. Am J Respir Cell Mol Biol. 1999;20:199-208.
9. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem. 1999; 274:21491-21494.
10. Nagase H. Activation mechanisms of matrix metalloproteinases. Biol Chem. 1997;378:151-160.
11. Robert V, Besse S, Sabri A, et al. Differential regulation of matrix metalloproteinases associated with aging and hypertension in the rat heart. Lab Invest. 1997;76:729-738.
12. Tyagi SC. Dynamic role of extracellular matrix metalloproteinases in heart failure. Cardiovasc Pathol. 1998;7:153-159.
13. Cleutjens JPM, Kandala JC, Guarda E, et al. Regulation of collagen degradation in the rat myocardium after infarction. J Mol Cell Cardiol. 1995; 27:1281-1292.
14. Brilla CG, Matsubara L, Weber KT. Advanced hypertensive heart disease in spontaneously hypertensive rats. Hypertension. 1996;28:269-275.
15. Dixon JMC, Ju H, Reid NL, et al. Cardiac collagen remodeling in the cardiomyopathic Syrian hamster and the effect of losartan. J Mol Cell Cardiol. 1997;29:1837-1850.
16. Tyagi SC, Kumar SG, Haas SJ, et al. Post-transcriptional regulation of extracellular matrix metalloproteinase in human heart end-stage failure secondary to ischemic cardiomyopathy. J Mol Cell Cardiol. 1996;28: 1415-1428.
17. Coker ML, Thomas CV, Clair MJ, et al. Myocardial matrix metalloproteinase activity and abundance with congestive heart failure. Am J Physiol. 1998;274:H1516-H1523.
18. Thomas CV, Coker ML, Zellner JL, et al. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation. 1998;97: 1708-1715.
19. Naito K, Kanbayashi N, Nakajima S, et al. Inhibition of growth of human tumor cells in nude mice by a metalloproteinase inhibitor. Int J Cancer. 1994;58:730-735.
20. Koike H, Tomioka S, Sorimachi H, et al. Membrane-anchored metalloproteinase MDC9 has an α-secretase activity responsible for processing the amyloid precursor protein. Biochem J. 1999;343:371-375.
21. Kumagai K, Ohno I, Okada S, et al. Inhibition of matrix metalloproteinases prevents allergen-induced airway inflammation in a murine model of asthma. J Immunol. 1999;162:4212-4219.
22. Thrailkill KM, Quarles LD, Nagase H, et al. Characterization of insulin-like growth factor-binding protein 5-degrading proteases produced throughout murine osteoblast differentiation. Endocrinology. 1995;136: 3527-3533.
23. Fowlkes JL, Suzuki K, Nagase H, et al. Proteolysis of insulin-like growth factor binding protein-3 during rat pregnancy: a role for matrix metalloproteinases. Endocrinology. 1994;135:2810-2813.
24. Hirschberg R, Kaysen GA. Insulin-like growth factor I and its binding proteins in the experimental nephrotic syndrome. Endocrinology, 1995; 136:1565-1571.
25. Fan J, Molina PE, Gelato MC, et al. Differential tissue regulation of insulin-like growth factor I content and binding proteins after endotoxin. Endocrinology. 1994;134:1685-1692.
26. Nagano M, Higaki J, Nakamura F, et al. Role of cardiac angiotensin II in isoproterenol-induced left ventricular hypertrophy. Hypertension. 1992; 19:708-712.
27. Ramchandran R, Kasturi S, Douglas JG, et al. Metalloprotease-mediated cleavage secretion of pulmonary ACE by vascular endothelial and kidney epithelial cells. Am J Physiol. 1996;271:H744-H751.
28. Boluyt MO, Long X, Eschenhagen T, et al. Isoproterenol infusion induces alterations in expression of hypertrophy-associated genes in rat heart. Am J Physiol. 1995;269:H638-H647.
29. Clarke MSF, Caldwell RW, Chiao H, et al. Contraction-induced cell wounding and release of fibroblast growth factor in heart. Circ Res. 1995; 76:927-934.
30. Schaub MC, Hefti MA, Harder BA, et al. Various hypertrophic stimuli induce distinct phenotypes in cardiomyocytes. J Mol Med. 1997;75: 901-920.
31. Benjamin IJ, Jalil JE, Tan LB, et al. Isoproterenol-induced myocardial fibrosis in relation to myocyte necrosis. Circ Res. 1989;65:657-670.
32. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation. 1991;83: 1849-1865.
33. Senzaki H, Gluzband YA, Pak PH, et al. Synergistic exacerbation of diastolic stiffness from short-term tachycardia-induced cardiodepression and angiotensin II. Circ Res. 1998;82:503-512.
34. Duivenvoorden WCM, Hirte HW, Singh G. Transforming growth factor β1 acts as an inducer of matrix metalloproteinase expression and activity in human bone-metastasizing cancer cells. Clin Exp Metastasis. 1999;17:27-34.